- Home
- HAFN vs IOVA Comparison
HAFN vs IOVA Comparison
Compare HAFN & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | IOVA |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 968.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HAFN | IOVA |
|---|---|---|
| Price | $5.27 | $2.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $6.50 | ★ $10.45 |
| AVG Volume (30 Days) | 1.2M | ★ 11.6M |
| Earning Date | 12-01-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $2,221,808,000.00 | $250,425,000.00 |
| Revenue This Year | N/A | $60.94 |
| Revenue Next Year | $0.20 | $60.85 |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $3.61 | $1.64 |
| 52 Week High | $6.64 | $8.15 |
Technical Indicators
Market Signals| Indicator | HAFN | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 26.54 | 66.78 |
| Support Level | $5.51 | $2.08 |
| Resistance Level | $5.40 | $2.60 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 0.00 | 91.33 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.